ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 64

Use of Moist Snuff and the Risk of Developing Rheumatoid Arthritis; Results From the Swedish Epidemiological Investigation of Rheumatoid Arthritis Study

Lars Alfredsson1, Lars Klareskog2 and Camilla Bengtsson1, 1Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 2Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Anti-citrullinated protein/peptide antibodies (ACPA) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Smoking is the major known environmental risk factor for RA, and notably this risk factor is exclusively seen in ACPA-positive RA. Whether this increased risk is due to nicotine or other substances of inhaled tobacco smoke is unclear. Smokeless tobacco contains nicotine and is often used as an alternative to smoking.  The role of smokeless tobacco in the etiology of RA has to date only been reported from a Swedish study based on male construction workers, where no association was observed between the use of moist snuff and the risk of RA1. However, whether smokeless tobacco is related to the ACPA-positive or ACPA-negative RA remains to be elucidated. In this report we aimed at investigating the association between the use of moist snuff and the risk of RA, and if this exposure has different impact on ACPA-positive and ACPA-negative disease.

Methods: Data from EIRA (Epidemiological Investigation of Rheumatoid Arthritis), a population-based case-control study from Sweden, was used. In total, information from1962 incident cases and 2247 randomly selected controls (matched on age, sex and residency), aged 18-70 years, was analysed. Ever, current and past moist snuff users were compared with never users. We calculated odds ratios (OR) with 95% confidence intervals (CI) for RA overall and the ACPA-positive and ACPA-negative subsets, by means of unconditional logistic regression models. All analyses were adjusted for age, sex, residency, pack-years of cigarette smoking and alcohol consumption.

Results: In total, 254 (13%) cases were ever moist snuff users compared with 290 (13%) controls, resulting in an odds ratio of 1.0 (95% CI 0.8-1.2). When exposure to moist snuff was analysed in relation to the incidence of ACPA-positive and ACPA-negative disease, no associations were observed. Furthermore, neither current nor past moist snuff use was related to the risk of RA, or the two sub-groups of the disease.

Conclusion: The use of moist snuff was not associated with RA risk, neither with regard to ACPA-positive nor ACPA-negative RA. The increased risk of RA associated with smoking may thus not be due to nicotine.

  1. Carlens C, et al: Smoking, Use of Moist Snuff, and risk of chronic inflammatory diseases. Am J Respir Crit Care Med. 2010;181:1217-22

Disclosure:

L. Alfredsson,
None;

L. Klareskog,
None;

C. Bengtsson,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-moist-snuff-and-the-risk-of-developing-rheumatoid-arthritis-results-from-the-swedish-epidemiological-investigation-of-rheumatoid-arthritis-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology